https://www.thebodypro.com/author/coverage-provided-mark-a-wainberg

Latest by Mark Wainberg, Ph.D.

Promo Image
Conference Coverage

The End of the Line for an Induction-Maintenance Approach to HIV Treatment Involving Zidovudine/Lamivudine/Abacavir?

The 8th International Congress on Drug Therapy in HIV Infection, held in Glasgow, Scotland, offered up considerable new information on antiretroviral chemotherapy. One important study conducted by Josep Mallolas and colleagues in Barcelona, Spain, de...

Promo Image
Conference Coverage

The Once-Daily Abacavir/Lamivudine Co-Formulation Proves Its Mettle by Being Both Safe and Effective

The combination of abacavir (ABC, Ziagen) and lamivudine (3TC, Epivir) is an attractive option as a nucleotide reverse transcriptase inhibitor (NRTI) backbone in antiretroviral therapy, because the combination permits a wide array of future NRTI opti...

Promo Image
Conference Coverage

Fosamprenavir Efficacy and Safety on Par With Other PIs, With No Gender-Based Differences

Fosamprenavir (FPV, 908, Lexiva, Telzir) is a potent protease inhibitor that was approved by the Food and Drug Administration in October 2003. Several studies have documented the safety and efficacy of once-daily fosamprenavir boosted with ritonavir ...

Promo Image
Cancer

Incidence of AIDS-Associated and Non-AIDS-Associated Malignancies Among HIV-Infected Individuals

Are HIV-infected people at greater risk for cancer? The answer, based on a number of studies, seems to be yes. But how much of a risk remains an ongoing question. Researchers are looking into determining whether the pathways of cancer development are...

Promo Image

Researchers Uncover Possible Alternative Pathway to Tenofovir Resistance

HIV has a remarkable ability to adapt to its surroundings. Thanks to its error-prone replication, the virus can develop mutations that confer a growth advantage in certain situations, such as in the presence of antiretroviral therapy. Although the fi...

Promo Image
Conference Coverage

Tenofovir Proves Safe for Kidneys After Three Years of Use

Treatment with antiretroviral agents is often fraught with a host of adverse effects. An emerging topic of great concern within the field of anti-HIV treatment relates to the fact that certain nucleoside/nucleotide reverse transcriptase inhibitors (N...

Promo Image

D-D4FC (RVT, Reverset) Is Active Against NRTI-Resistant Virus in Phase 2B Trial

HIV drug resistance is a growing problem with all antiretrovirals, so there is a great deal of interest in new drugs that may retain activity against mutations associated with resistance. The current study by Cal Cohen, of the Community Research Init...

Promo Image
Blood Disorders

Incidence of Zidovudine-Associated Anemia May Be Lower Than Initially Thought -- Particularly With Fixed-Dose Combinations

In the beginning, there was zidovudine (AZT, Retrovir). As the first antiretroviral drug approved for the treatment of HIV, its benefits during the early years of the epidemic were incalculable. However, zidovudine's use also had at least one downsid...

Promo Image
Hepatitis C

Adverse Event Risk on Abacavir + Lamivudine Is Not Higher for Patients Coinfected With Hepatitis B and/or Hepatitis C

How safe are antiretroviral nucleosides in HIV-infected individuals who are coinfected with hepatitis B or hepatitis C? The question is an important one, because of two reasons: Firstly, up to one third of people with HIV are coinfected with hepatiti...

Promo Image

Vicriviroc (SCH 417690, SCH-D), a CCR5 Antagonist, Generally Well Tolerated and Effective in 14-Day Monotherapy Study

IAS 2005 featured a bevy of oral presentations on CCR5 antagonists, a new class of HIV medications in development that seeks to prevent HIV from binding to the CCR5 cellular co-receptor, which facilitates HIV's entry into the host cell.

This study r...